Article

OccuLogix finalizes SOLX acquisition

OccuLogix Inc. has completed its acquisition of SOLX Inc. OccuLogix acquired SOLX by way of a merger of SOLX and a wholly owned subsidiary of OccuLogix, with SOLX surviving the merger and becoming the wholly owned subsidiary of OccuLogix.

OccuLogix Inc. has completed its acquisition of SOLX Inc. OccuLogix acquired SOLX by way of a merger of SOLX and a wholly owned subsidiary of OccuLogix, with SOLX surviving the merger and becoming the wholly owned subsidiary of OccuLogix.

SOLX’s President and Chief Executive Officer (CEO) Doug Adams has joined OccuLogix as the president of the new subsidiary.

“We are very excited to welcome Doug and his entire team at SOLX to the OccuLogix family,” said OccuLogix Chairman and CEO Elias Vamvakas. “Our objective is to build a leading ophthalmic device company that is focused on age-related eye diseases.

“We are confident that the acquisition of SOLX will demonstrate our ability to identify and then acquire or partner with new technologies that leverage our expertise in sales, marketing, and regulatory along with our existing sales footprint to bring new therapies to market successfully,” added Vamvakas.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.